Psychiatry and Neurology, Neurology · Loma Linda, CA
NPI
1053358457
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
11370 Anderson St, Suite 2400
Loma Linda, CA, 92354
Phone (909) 558-2880
Groups this clinician bills Medicare through
Medicare paid, 2024
$277K
34,717 services
Medicare patients, 2024
212
Average age 73
Drug cost, 2024
$4.1M
3,613 prescriptions
Company payments, 2025
$528K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Khashayar Dashtipour was code J0588 (injection, incobotulinumtoxin a, 1 unit), 13,800 times for 33 patients. In total Khashayar Dashtipour billed 34,717 services in 26 codes, and Medicare paid $277K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-07-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 13,800 | 33 | $4.08 | $56K |
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 5,890 | 15 | $4.92 | $29K |
| J0587 Injection, rimabotulinumtoxinb, 100 units | Office | 5,630 | 15 | $10.13 | $57K |
| J0589 Injection, daxibotulinumtoxina-lanm, 1 unit | Office | 4,910 | 14 | $3.39 | $17K |
| 99215 Office E&M - Established | Office | 323 | 147 | $129.95 | $42K |
| 99214 Office E&M - Established | Office | 171 | 114 | $94.56 | $16K |
| 64616 Musculoskeletal | Office | 56 | 23 | $160.49 | $8,987 |
| 64611 Musculoskeletal | Office | 41 | 17 | $96.47 | $3,955 |
| 64612 Musculoskeletal | Office | 41 | 17 | $137.58 | $5,641 |
| 99205 Office E&M - New | Office | 40 | 40 | $137.95 | $5,518 |
| 64644 Musculoskeletal | Office | 32 | 12 | $146.44 | $4,686 |
| 96372 Injection Administration | Office | 17 | 14 | $11.86 | $202 |
By year: 2022 $221K for 19,108 services; 2023 $187K for 15,426 services; 2024 $277K for 34,717 services.
Medicare prescription drug claims, 2024
In 2024, the drug Khashayar Dashtipour prescribed most often to Medicare patients was Rytary (Carbidopa/Levodopa), with 439 prescriptions and refills. In total Khashayar Dashtipour wrote 3,613 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rytary Carbidopa/Levodopa | 439 | 606 | 68 | $479K |
| Carbidopa-Levodopa Carbidopa/Levodopa | 438 | 829 | 109 | $16K |
| Quetiapine Fumarate Generic | 210 | 304 | 45 | $2,321 |
| Gabapentin Generic | 208 | 316 | 48 | $3,237 |
| Amantadine Amantadine Hcl | 187 | 340 | 40 | $9,242 |
| Escitalopram Oxalate Generic | 172 | 288 | 44 | $1,316 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 152 | 283 | 40 | $4,889 |
| Primidone Generic | 130 | 260 | 33 | $4,007 |
| Nuplazid Pimavanserin Tartrate | 126 | 140 | 16 | $734K |
| Selegiline Hcl Generic | 107 | 217 | 26 | $12K |
| Donepezil Hcl Generic | 98 | 194 | 27 | $1,399 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 86 | 173 | 21 | $1,672 |
| Austedo Xr Deutetrabenazine | 82 | 82 | Under 11 | $693K |
| Rasagiline Mesylate Generic | 77 | 179 | 20 | $19K |
| Nourianz Istradefylline | 68 | 141 | 16 | $278K |
Brand drugs: 1,147 claims; generic drugs: 2,466 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Khashayar Dashtipour $528K ($528K in general payments such as food, travel and fees) from 16 companies. The largest payer was MDD US Operations, LLC with $162K.
| Company | Payments | Amount |
|---|---|---|
| MDD US Operations, LLC | 112 | $162K |
| Teva Pharmaceuticals USA, Inc. TEVA | 65 | $135K |
| Biogen, Inc. BIIB | 35 | $75K |
| Abbvie Inc. ABBV | 70 | $63K |
| Amneal Pharmaceuticals LLC AMRX | 26 | $31K |
| ACADIA Pharmaceuticals Inc ACAD | 14 | $24K |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 9 | $19K |
| Merz Pharmaceuticals, LLC | 9 | $13K |
| Tanabe Pharma America, Inc. | 3 | $4,537 |
| Medtronic, Inc. MDT | 6 | $335 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.